About velmanase alfa
Recombinant lysosomal alpha-mannosidase enzyme
Used for
- Enzyme replacement therapy for non-central nervous system manifestations of alpha-mannosidosis.
Usual adult dose
1 mg/kg by intravenous infusion once weekly.
Usual dose in children
1 mg/kg by intravenous infusion once weekly; approved for children aged 6 months and older.
Common side effects
- Infusion-related reactions, including fever, chills, rash, or breathing difficulty
- Headache
- Joint pain
- Nausea
Important warnings
- Serious allergic reactions, including anaphylaxis, can occur during or after infusion.
- Infusions require monitoring; reactions may need treatment or infusion interruption.
- Antibodies to the medicine may develop and affect treatment response.
- It does not treat central nervous system manifestations.
Pregnancy
Human pregnancy data are limited; use only when the potential benefit justifies potential fetal risk.
Breastfeeding
It is unknown whether velmanase alfa passes into human milk; consider treatment benefits and breastfeeding needs.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.